IC
MNPR icon

Ikarian Capital’s Monopar Therapeutics MNPR Stock Holding History

Ikarian Capital’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,908
Closed -$215K – 172
2025
Q1 		$215K Hold
5,908
– – 0.03% 136
2024
Q4 		$130K Buy
+5,908
New +$99.1K 0.02% 153

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's MNPR Position: Q2 2025 in Review

Ikarian Capital sold out of Monopar Therapeutics (MNPR) in Q2 2025, closing a stake of 5,908 shares — an estimated $215K sold.

Ikarian Capital first reported a position in MNPR in Q4 2024 and held it in 2 quarters. The position peaked at $215K in Q1 2025. 43 funds tracked by Wall St. Rank hold MNPR as of Q2 2025.

  • Ikarian Capital reported no remaining Monopar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 5,908 Monopar Therapeutics shares in Q2 2025, an estimated $215K.
  • Ikarian Capital first reported a position in Monopar Therapeutics in Q4 2024 and held it in 2 quarters.
  • Ikarian Capital's Monopar Therapeutics position peaked at $215K in Q1 2025.
  • 43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.